Crystalys gets $130M to take Sobi-rivaling gout drug to market
Crystalys raised $130M to advance its Sobi-rivaling gout drug through Phase 3 testing.
Crystalys Therapeutics
Private
Crystalys Therapeutics is a clinical-stage biotechnology company developing dotinurad, a Phase 3-ready URAT1 inhibitor for the treatment of gout. The company's lead asset is positioned to rival Sobi's gout franchise.
Company Info
Sector:Biotechnology
Headquarters:San Diego, California, USA
Founded:2022
Website:crystalystx.com/
Funding Round:Series B
Total Funding:$130M (Series B, July 2026)
Funding & Investor Relations
IPO Outlook / Plans
TBD
Upcoming Milestones & Key Dates
Q4 2026
Clinical
Phase 3 dosing initiation
2027
Financing
Series C or IPO consideration
Clinical Development Pipeline
Dotinurad
Target: URAT1Undisclosed
Target: TBDUndisclosed
Target: TBDRecent News
Crystalys nets $130M more to push gout drug through late-stage tests
Crystalys raised $130M to push its gout drug dotinurad through late-stage testing.
Crystalys mines $130M series B to push gout drug through phase 3
Crystalys raised a $130M series B to push its gout drug through phase 3 testing.
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug.
Leadership Team
Jim Kenealy
Co-Founder and Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer